For the year ending 2025-12-31, BDTX had -$15,437K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 22,367 |
| Stock-based compensation expense | 6,628 |
| Depreciation expense | 325 |
| (accretion) amortization on investments | 1,279 |
| Non-cash rent expense | 3,054 |
| Gain on sale of investments | 74 |
| Impairment of right-of-use assets and property and equipment | 7,348 |
| Gain on sale of property and equipment | 27 |
| Prepaid expenses and other current assets | 349 |
| Other non-current assets | -176 |
| Accounts payable | -3,428 |
| Accrued expenses and other current liabilities | -1,414 |
| Non-current operating lease liability | -3,713 |
| Net cash provided by (used in) operating activities | 29,614 |
| Proceeds from disposal of equipment | 27 |
| Proceeds from sales and maturities of investments | 119,094 |
| Purchases of investments | 164,026 |
| Net cash provided by (used in) investing activities | -44,905 |
| Proceeds from exercise of common stock options and espp, net of restricted stock surrendered for taxes | -146 |
| Proceeds from issuance of common stock, net of issuance costs | 0 |
| Net cash provided by (used in) financing activities | -146 |
| Net (decrease) increase in cash and cash equivalents | -15,437 |
| Cash, cash equivalents and restricted cash, beginning of year | 37,256 |
| Cash, cash equivalents and restricted cash, end of year | 21,819 |
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)